ArticlePediatric nephrology (Berlin, Germany)2016
Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases.
Article in Pediatric nephrology (Berlin, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Article
- Targeting interleukin-1 signaling for renoprotection.Frontiers in immunology · 2025Review
- The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever.Clinical rheumatology · 2024Article
- Efficacy of canakinumab on AA amyloidosis in late-onset NLRP3-associated autoinflammatory disease with an I574F somatic mosaic mutation.Clinical rheumatology · 2022Review
- Evaluation of the international severity score for FMF (ISSF) scores in Turkish children diagnosed with FMF: a single-center experience.Clinical rheumatology · 2021Article
- Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases.Frontiers in pediatrics · 2021Article
- Article
- Additional Benefit of Canakinumab on Proteinuria in a Case With Muckle-Wells Syndrome in Remission Under Anakinra.Archives of rheumatology · 2020Article
- Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis.Rheumatology international · 2020Review
- What's new in autoinflammation?Pediatric nephrology (Berlin, Germany) · 2019Review
- Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases.International journal of molecular sciences · 2019Review
- Article
- Canakinumab treatment in children with familial Mediterranean fever: report from a single center.Rheumatology international · 2018Article
- Rapid clinical improvement of amyloid A amyloidosis following treatment with tocilizumab despite persisting amyloid deposition: a case report.BMC nephrology · 2017Article
- Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient.Paediatric drugs · 2017Review
- Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for Management.Frontiers in immunology · 2017Review
- The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever.Molecular and cellular pediatrics · 2016Article
- Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade.Current opinion in rheumatology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmyloidosis may complicate autoinflammatory diseases (AID). We aimed to evaluate the renal biopsy findings, and clinical and laboratory parameters in patients with AID-associated amyloidosis who have responded to anti-interleukin 1(IL1) treatment.
methodsTwo children with systemic juvenile idiopathic arthritis and one with cryopyrin-associated periodic syndrome diagnosed as having reactive amyloidosis were treated with anti-IL1 drugs. The renal histopathological findings at the time of diagnosis of amyloidosis and after the onset of anti-IL1 were evaluated according to the amyloid scoring/grading system.
resultsThe median age of disease onset and diagnosis of amyloidosis were 3 and 12 years, respectively. Anakinra was started in all; however, anakinra caused a local cutaneous reaction in one, thus canakinumab was commenced. Proteinuria improved in all. Control renal biopsies were performed a median of 3 years after the first biopsies. The renal amyloid prognostic score did not improve in patient 1, and progressed in patients 2 and 3. The renal amyloid grade progressed in patient 2.
conclusionsThis is the first series demonstrating progression of renal tissue damage after the improvement of proteinuria with anti-IL 1 in AID-associated amyloidosis. Anti-IL1 drugs are important to prevent further amyloid accumulation; however, new treatment strategies are needed to target the amyloid deposits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.